A Phase 2, Multicenter, Randomized, Double-Blind, Vehicle Controlled, Parallel-Group, Clinical Study Comparing the Efficacy and Safety of IDP-126 Gel in the Treatment of Acne Vulgaris
Phase of Trial: Phase II
Latest Information Update: 13 Jul 2018
At a glance
- Drugs IDP 126 (Primary)
- Indications Acne vulgaris
- Focus Therapeutic Use
- Sponsors Bausch Health Companies; Ortho Dermatologics
- 13 Jul 2018 According to a Bausch Health Companies media release, Valeant Pharmaceuticals International changed its name to Bausch Health Companies.
- 03 Jul 2018 Planned End Date changed from 18 Aug 2018 to 18 Dec 2018.
- 03 Jul 2018 Planned primary completion date changed from 18 Jun 2018 to 18 Oct 2018.